Brian Abrahams
Stock Analyst at RBC Capital
(2.07)
# 2,967
Out of 4,953 analysts
426
Total ratings
41.35%
Success rate
-8.97%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics | Maintains: Outperform | $20 → $19 | $9.80 | +93.88% | 4 | Aug 14, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $57 → $55 | $37.36 | +47.22% | 15 | Aug 12, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $60 → $63 | $49.59 | +27.04% | 21 | Aug 8, 2025 | |
| GILD Gilead Sciences | Maintains: Sector Perform | $96 → $98 | $117.98 | -16.94% | 32 | Aug 8, 2025 | |
| ETNB 89bio | Maintains: Sector Perform | $12 → $11 | $9.01 | +22.15% | 15 | Aug 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $39 → $40 | $24.97 | +60.19% | 2 | Aug 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $430 → $405 | $390.76 | +3.64% | 55 | Aug 5, 2025 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $18 → $10 | $8.52 | +17.37% | 11 | Aug 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $688 → $695 | $571.78 | +21.55% | 33 | Aug 4, 2025 | |
| BIIB Biogen | Maintains: Outperform | $208 → $219 | $138.86 | +57.71% | 39 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $146 → $144 | $132.86 | +8.38% | 21 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $68 → $72 | $85.46 | -15.75% | 22 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $23 | $20.18 | +13.97% | 35 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $8.28 | +57.00% | 19 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $75 | $61.49 | +21.97% | 1 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $52.66 | +27.23% | 2 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $9.30 | +233.33% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $1.5 | $0.48 | +209.92% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $33 | $6.22 | +430.55% | 12 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $58 | $9.18 | +531.81% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $36.54 | +129.89% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $12.55 | +147.01% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $4 → $3 | $1.47 | +104.08% | 13 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $1.61 | +148.45% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $111.29 | +28.49% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $24.37 | +64.17% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $30 | $32.10 | -6.54% | 11 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $9.39 | +134.29% | 9 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $8.47 | +77.20% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $3.97 | +126.70% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $33 | $63.65 | -48.15% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $29.12 | - | 4 | Dec 4, 2017 |
Aardvark Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $9.80
Upside: +93.88%
Xenon Pharmaceuticals
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $55
Current: $37.36
Upside: +47.22%
PTC Therapeutics
Aug 8, 2025
Maintains: Outperform
Price Target: $60 → $63
Current: $49.59
Upside: +27.04%
Gilead Sciences
Aug 8, 2025
Maintains: Sector Perform
Price Target: $96 → $98
Current: $117.98
Upside: -16.94%
89bio
Aug 8, 2025
Maintains: Sector Perform
Price Target: $12 → $11
Current: $9.01
Upside: +22.15%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Outperform
Price Target: $39 → $40
Current: $24.97
Upside: +60.19%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $430 → $405
Current: $390.76
Upside: +3.64%
Prothena Corporation
Aug 5, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $8.52
Upside: +17.37%
Regeneron Pharmaceuticals
Aug 4, 2025
Maintains: Sector Perform
Price Target: $688 → $695
Current: $571.78
Upside: +21.55%
Biogen
Aug 1, 2025
Maintains: Outperform
Price Target: $208 → $219
Current: $138.86
Upside: +57.71%
Jul 31, 2025
Maintains: Outperform
Price Target: $146 → $144
Current: $132.86
Upside: +8.38%
Jul 30, 2025
Maintains: Sector Perform
Price Target: $68 → $72
Current: $85.46
Upside: -15.75%
Jul 17, 2025
Maintains: Sector Perform
Price Target: $25 → $23
Current: $20.18
Upside: +13.97%
Jun 30, 2025
Reiterates: Outperform
Price Target: $13
Current: $8.28
Upside: +57.00%
Jun 24, 2025
Maintains: Outperform
Price Target: $35 → $75
Current: $61.49
Upside: +21.97%
Jun 3, 2025
Reiterates: Outperform
Price Target: $67
Current: $52.66
Upside: +27.23%
May 15, 2025
Reiterates: Outperform
Price Target: $31
Current: $9.30
Upside: +233.33%
May 14, 2025
Reiterates: Sector Perform
Price Target: $1.5
Current: $0.48
Upside: +209.92%
May 13, 2025
Maintains: Outperform
Price Target: $34 → $33
Current: $6.22
Upside: +430.55%
May 7, 2025
Maintains: Outperform
Price Target: $65 → $58
Current: $9.18
Upside: +531.81%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $36.54
Upside: +129.89%
Mar 7, 2025
Initiates: Outperform
Price Target: $31
Current: $12.55
Upside: +147.01%
Mar 4, 2025
Maintains: Sector Perform
Price Target: $4 → $3
Current: $1.47
Upside: +104.08%
Mar 4, 2025
Reiterates: Sector Perform
Price Target: $4
Current: $1.61
Upside: +148.45%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $111.29
Upside: +28.49%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $24.37
Upside: +64.17%
Nov 1, 2024
Maintains: Sector Perform
Price Target: $32 → $30
Current: $32.10
Upside: -6.54%
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $9.39
Upside: +134.29%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $8.47
Upside: +77.20%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $3.97
Upside: +126.70%
Nov 3, 2021
Maintains: Sector Perform
Price Target: $21 → $33
Current: $63.65
Upside: -48.15%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $29.12
Upside: -